ArticleVirology journal2025
HIV-1 drug resistance and molecular transmission network analysis of newly diagnosed people living with HIV in Beijing, China: a retrospective study from 2015 to 2023.
Article in Virology journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Advancing Precision Public Health: an implementation science framework for HIV Cluster Detection and Response driven by molecular epidemiology.Frontiers in public health · 2026Article
- Molecular transmission network analysis of HIV-1 among older adults in Central China: a cross-sectional study in Shaodong City.Frontiers in microbiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAlthough the annual number of newly reported human immunodeficiency virus (HIV) infections in Beijing has shown a continuous decline since 2016, the population of people living with HIV (PLWH) has maintained a persistent upward trend. This retrospective study aimed to analyse data from newly diagnosed PLWH from 2015 to 2023 in Beijing to develop precision interventions.
methodsAll newly diagnosed PLWH were subjected to sequence splicing, quality control, information matching, and analysis for pretreatment drug resistance (PDR) and molecular transmission network. The Stanford Drug Resistance Database was used to analyse drug resistance, and Hyphy and Cytoscape software were used to construct a molecular transmission network with the gene distance threshold of 0.015.
resultsA total of 3,569 newly diagnosed PLWH were included in this study. A total of 42 HIV-1 subtypes were identified, with CRF01_AE being the most common subtype, followed by the CRF07_BC and B subtypes. However, for the first time, the dominant strain shifted from CRF01_AE to CRF07_BC in 2023. A total of 340 drug-resistant sequences were obtained, and the overall prevalence of PDR was 9.53% from 2015 to 2023. The most common mutations were distributed among V179, K103, M184, S68 and M46, which presented diverse distributions and combined mutation features. A total of 64 transmission clusters were identified in the network, among which CRF07_BC was dominated by large spreading clusters, whereas CRF01_AE was dominated by small- and medium-sized spreading clusters. The largest cluster for CRF07_BC expanded rapidly from 8 cases in 2015 to 161 cases in 2023.
conclusionsThis study revealed the prevalence of HIV-1 drug resistance and molecular transmission network in Beijing. The change in the dominant HIV strain of participants should be emphasized. Subtype CRF07_BC is prone to forming fast-spreading clusters, and targeted interventions should be designed to prevent high-risk transmission sources and reduce new HIV infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.